Contents

1  Introduction ........................................................................................................................................... 2

2  Statement for the disclosure of 2019 data during the COVID-19 pandemic in 2020 ......................... 2

3  Definition of Transfers of Value ........................................................................................................... 3

4  Definition and management of Cross-Border Spend ............................................................................ 4

5  Which Recipients of Transfers of Value are reported by Gilead ......................................................... 4

6  How Transfers of Value are captured and recorded by Gilead ............................................................ 5

   6.1  Direct Spend ..................................................................................................................................... 5

   6.2  Indirect Spend ................................................................................................................................. 5

   6.3  ToV Dates ....................................................................................................................................... 5

   6.4  Treatment of Tax ........................................................................................................................... 5

   6.5  Currency Management .................................................................................................................. 5

7  How Gilead manages Consent .............................................................................................................. 6

8  How Gilead avoids reporting duplicate transactions ........................................................................... 6

9  How Gilead checks the accuracy of reports .......................................................................................... 6

10 Publication of reports ............................................................................................................................ 7

11 Glossary ............................................................................................................................................... 8
1 Introduction

This methodological note is intended to help readers understand how the Transfers of Value (ToVs) from Gilead Sciences Inc. and its Affiliates (Gilead) to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) in the UK have been collated and reported. A glossary has been included at the end of this methodological note containing an alphabetical list of the main terms used within this note and their definitions. The terms in the glossary are always capitalised and appear in bold on first use within this note to aid lookup. The glossary also contains hyperlinks to other terms defined within the glossary to aid understanding.

Gilead has no “over the counter” medicines and no medical devices, so all Transfers of Value relate to prescription-only medicines, i.e. those medicines that must be prescribed by a suitably qualified HCP.

Gilead began its EFPIA transparency reporting project in 2013 to supplement existing country transparency reporting mechanisms in Denmark, France, Netherlands, Portugal, and UK. This was to ensure that Gilead would be ready to capture all relevant ToVs to Reportable Recipients prospectively throughout 2015 prior to the first EFPIA disclosure in 2016.

To enable Gilead to have assurance that all ToVs to all Reportable Recipients will be reported in the correct format and language(s) for each country, it was decided to automate and standardise data extraction as far as possible and to use a Reporting Engine supplied by a Reporting Engine Provider to produce the reports. Gilead also uses the Reporting Engine Provider’s HCP / HCO master data to confirm Reportable Recipients, which supports Gilead’s data accuracy efforts.

To help with checking and managing the data locally, Gilead has engaged a Transparency & Monitoring Specialist for each Gilead Affiliate who is responsible for ensuring completeness and accuracy of data.

2 Statement for the disclosure of 2019 data during the COVID-19 pandemic in 2020

As part of the pharmaceutical industry’s annual disclosure of transfers of value to HCPs, ORDMs and HCOs via the Disclosure UK platform and in order to ensure accuracy of the published data, the ABPI writes to all of the HCPs, ORDMs and HCOs named in companies’ disclosure data ahead of its publication on Disclosure UK at the end of June. (Over 20,000 in June 2019.)

Given the unprecedented pressure on the NHS and health care professionals in responding to the COVID-19 pandemic, in April 2020 the ABPI and PMCPA agreed that it would not be appropriate for industry to write to HCPs, ORDMs or HCOs to request that disclosure data be reviewed. Doing so would add additional work for NHS professionals at this time. To avoid this, and in-line with guidance provided by the ABPI, GILEAD’s 2019 transfer of value data has been published on Disclosure UK in aggregate.
Commitment to transparency

The pharmaceutical industry is committed to preserving the integrity of Disclosure UK and transparency in our interactions with HCPs, ORDMs and HCOs. The ABPI continues to explore how the full disaggregated 2019 data can be submitted to Disclosure UK in line with data from previous years.

3 Definition of Transfers of Value

ToVs may arise from the following broad types of activity (there are others):

a. **Advisory Boards** - HCPs give Gilead independent advice and contribute with their expertise on particular aspects of Gilead’s strategy or the use of Gilead’s medicines, where the knowledge cannot be obtained within Gilead. Gilead may pay an honorarium to each participant and / or pay their travelling expenses to the place where the meeting is being held.

b. **Meetings** - Gilead arranges meetings for HCPs on different topics such as education on a specific therapy area or other scientific events. The knowledge and expertise of HCPs are often needed to help conduct these events. Gilead may pay an honorarium and/or travelling expenses to the consultants participating in these events.

c. **HCP Sponsorship** – Gilead may Sponsor one or more HCPs to attend a scientific conference or congress which might include paying the HCPs’ conference fees and / or their travelling expenses.

d. **HCO Sponsorship** - Gilead may Sponsor one or more HCOs who will choose which HCPs to send to a conference. In this case, Gilead does not know which HCPs received the ToVs and will therefore report the ToVs against the relevant HCOs.

e. **Clinical trials** prior to approval - Gilead pays HCOs to participate in clinical trials which are an essential part of ensuring that medicines are effective and have an appropriate safety profile. Gilead may also pay travelling expenses for HCPs involved in clinical trials to travel to meetings with other HCPs involved in the same clinical trials. Note that clinical trials ToVs are reported within the single figure for research and development activities within each country provided the ToVs fall within the scope of the original agreed trial protocol; any ToVs outside of that scope are reported as fees for services and associated travelling expenses.

f. **Market research** - small ToVs might be made to HCPs in return for answering questions about Gilead products and / or a therapeutic area. Gilead only participates in “blind” market research where it does not know the identities of the participants. Gilead has therefore not reported any ToVs for market research activities.

g. **Investigator Sponsored Research** – research may be undertaken by individual HCPs and / or HCOs where they would like to investigate a particular aspect of a Gilead medicine. This type of research, where supported by paying a Grant to the relevant HCO, is reported as a ToV under the appropriate heading.

h. **Grants, Donations and benefits in kind** – Gilead may make grants or donations to HCOs to enhance patient care, or benefit the NHS and maintain patient care, or for the purpose of supporting research.
i. Joint Working – Gilead may work in collaboration with the NHS on activities which benefit patients where there is a shared commitment to successful delivery.

j. Note that food and drink is not reportable under the EFPIA Disclosure Code.

4 Definition and management of Cross-Border Spend

Some ToVs to Reportable Recipients are made by a Gilead Affiliate, or on behalf of a Gilead Affiliate, that is not the “home country” (country of principal practice) of the HCP or HCO receiving the ToVs. For example, Gilead UK might make ToVs to a German HCP, or an events agency working for Gilead’s European Head Office might make ToVs to several HCPs from different countries. This is called Cross-Border Spend.

Any ToVs made by, or on behalf of, any Gilead Affiliates to Reportable Recipients within EFPIA countries, including Cross-Border Spend, are captured as described under “How Transfers of Value are captured and recorded by Gilead”.

5 Which Recipients of Transfers of Value are reported by Gilead

Gilead has flagged all Reportable Recipients as defined under the EFPIA Disclosure Code within its internal systems to aid extraction of relevant ToVs. The Reportable Recipients are defined in the Glossary.

Where HCPs have set up separate legal entities through which to deliver their services, Gilead discloses the transfer of value under the names of the HCPs themselves wherever clearly identifiable; otherwise, the transfer of value is disclosed under the name of the legal entity, being treated as an HCO.

Where Gilead has made a transfer of value to a department within an HCO, that transfer of value is disclosed under the name of the HCO, not the department.

In the UK the local reporting template used is in English. Professional Congress Organisers (PCO) are not reportable recipients. Transfers of Values made to PCOs are disclosed under the end recipients (HCOs or HCPs) if they are clearly identifiable and the exact values transferred to them are made available by the PCOs.

Joint Working Project

Gilead works in collaboration with the NHS where, for the benefit of the patients, skills, experience, and/or resources are pooled for the joint development and implementation of patient centred projects and where there is a shared commitment to successful delivery.

The Joint Working Projects Gilead has contributed to in 2019 can be found below:


Page 4 of 10
6 How Transfers of Value are captured and recorded by Gilead

6.1 Direct Spend
Gilead makes some ToVs directly to HCPs and HCOs; these transfers are referred to as Direct Spend. Direct Spend typically covers items such as fees for services and associated travelling expenses, plus any non-monetary ToVs made to HCPs via Gilead employee out-of-pocket expenses.

Gilead has modified its Enterprise Resource Planning (ERP) system and employee expense reimbursement system to extract all Direct Spend to any Reportable Recipient into a standardised format. These data are uploaded into an internal database where they are checked and stored temporarily before being transferred to the Reporting Engine.

6.2 Indirect Spend
ToVs made to HCPs and HCOs by Third Party Vendors on behalf of Gilead are called Indirect Spend. Indirect Spend typically covers travel and accommodation at meetings and conferences, and may also include honoraria payments.

Gilead uses a template Excel spreadsheet to enable Third Party Vendors to capture ToVs to Reportable Recipients. The template Excel spreadsheet provides data in the same standardised format, which are then treated in the same way as for Direct Spend as described above.

6.3 ToV Dates
The date recorded against each ToV determines the ToV reporting period. The ToV date recorded by Gilead is the payment date except for the following instances:

a. Air / Rail Travel: The ToV date is the date the travel ticket is issued (i.e. the date on which Gilead has committed to the travel);

b. Travel Transfers: The ToV date is the date the transfer was provided; and

c. Accommodation: The ToV date is the latest date on which the accommodation was provided (i.e. the last day of the hotel stay).

For joint working activities, the assignment of the ToV to the NHS partner is made on the date that the NHS or other service provider (for example where Gilead’s contribution is through funding services via a third party) receives payment from Gilead. Thus for activities that take place over a number of years, the ToVs will be disclosed in the year in which the payment is made.

Some payments were made in 2019 for activities that occurred in 2018, and these are reported as ToVs in the 2019 report. Equally, some payments were made, and will be reported, in 2019 that relate to activities that will occur in 2020.

6.4 Treatment of Tax
The ABPI implementation of the EFPIA Disclosure Code permits companies to choose whether to report ToVs inclusive or exclusive of taxes, Gilead has chosen to report inclusive of taxes.

6.5 Currency Management
Each ToV is transferred to the Reporting Engine in its original currency. The Reporting Engine has the capability to convert the ToV into any currency enabled within the system. This permits Gilead to publish the required local report in local currency, albeit some ToVs may have been made in a currency other than the local currency.
The Reporting Engine Provider maintains exchange rates within the Reporting Engine using rates obtained from a well-known, reputable provider.

7 How Gilead manages Consent

As required by local Data Privacy legislation Gilead has sought Consent from Reportable Recipients for individual disclosure of their ToVs in the ABPI Report. Such Consent has been obtained by reporting period.

Gilead does not permit “cherry-picking”: either all ToVs made to a Reportable Recipient in a reporting period are disclosed individually, or they are disclosed in aggregate.

Following the implementation of the new General Data Protection Regulation (GDPR) on 25th of May 2018, this year’s disclosure is fully compliant with the new requirements. For reports from previous years, where consent to disclose is not considered to be compliant with the new requirements, the ToVs disclosed against individuals are reallocated to the aggregate section and an updated report is produced to replace the previous one.

8 How Gilead avoids reporting duplicate transactions

Gilead has put in place several steps to ensure that ToVs are reported only once. The key step is that the Gilead Affiliate that makes the ToV is responsible for capturing the ToV.

Where Gilead works with other pharmaceutical companies, each company reports the ToVs relating to the activities that they organised. For jointly organised events, the companies agree in advance which ToVs will be reported by each company. This mechanism avoids duplicate reporting for joint activities.

Transparency & Monitoring Specialists are responsible for reviewing Reportable Recipient ToVs in the Reporting Engine and taking reasonable steps to identify and resolve any potential duplicates.

9 How Gilead checks the accuracy of reports

In addition to the steps above to prevent duplicate ToVs, Transparency & Monitoring Specialists also review Reportable Recipient ToVs in the Reporting Engine for accuracy and completeness. Some of the activities they undertake as part of this review may include:

a. Identifying inconsistencies in the ABPI Report output, such as travelling expenses associated with services with no fees for services, or travelling expenses related to Sponsorship of cost of events without any associated registration costs;
b. Sample checking ToVs back to source documentation, such as signed contracts or supplier invoices; and
c. Tracing expected ToVs from planning documents through to the Reporting Engine;
d. Before the disclosure publication, reportable recipients are given the opportunity to review the ToVs associated with them, and request amendment if required.

Such activities as those described above give Gilead reasonable assurance that the ToVs it reports are as accurate and complete as possible.
10 Publication of reports

Transparency & Monitoring Specialists are responsible for producing the local report required under their local EFPIA Disclosure Code implementation and publishing it appropriately. The ABPI report is published on the ABPI central platform.

Reportable Recipients may notify Gilead of any errors in reporting, or withdraw their Consent at any time.

Gilead’s document retention period is 10 years in lieu of any statutory retention period.

Any queries regarding Gilead’s EFPIA reporting should be addressed to public_affairs@gilead.com.

June 2020
### 11 Glossary

This glossary includes the technical definitions of all terms used within this methodological note, including relevant abbreviations.

<table>
<thead>
<tr>
<th>Term</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consent</td>
<td>Consent refers to the Reportable Recipient agreeing to Gilead’s use and disclosure of that Reportable Recipient’s personal data for Data Privacy purposes. To be valid, Consent must be given freely and must be informed. For Consent to be ‘informed’, Gilead must tell the Reportable Recipient in advance of Consent being given: (i) what personal data of that Reportable Recipient Gilead wants to collect; and (ii) how Gilead intends to use that personal data. Consent can be withdrawn by the relevant Reportable Recipient at any time by giving notice to Gilead.</td>
</tr>
<tr>
<td>Cross-Border Spend</td>
<td>Any payment made by one Gilead group company to a payee (Reportable Recipient) who is reportable by another Gilead Affiliate (e.g. a payment made by the UK Affiliate to a German HCP is reportable by Gilead Germany).</td>
</tr>
<tr>
<td>Data Privacy / Data Protection</td>
<td>The laws relating to processing of personal data (information relating to an identifiable person), including General Data Protection Regulation (GDPR) and national legislation implementing the same.</td>
</tr>
</tbody>
</table>
| Transparency & Monitoring Specialist | The Transparency & Monitoring Specialist is the individual in each Gilead Affiliate who is responsible for:  
• generating, maintaining and publishing disclosure reports  
• co-ordinating communications with Reportable Recipients and taking appropriate action to resolve any identified issues |
| Direct Spend                      | Direct spend means all Transfers of Value to a Reportable Recipient made directly by Gilead. In other words, all sums paid by Gilead directly to a Reportable Recipient. This spend is recorded in Gilead’s ERP (finance) system. See also Indirect Spend. |
| Donation                          | Philanthropic payment to a registered charity. |
| EFPIA                             | EFPIA or the ‘European Federation of Pharmaceutical Industries and Associations’ is the body that represents the pharmaceutical industry in Europe. Further information can be found here. |
| EFPIA Disclosure Code             | EFPIA’s code sets out requirements for the disclosure by the pharmaceutical industry of its financial interactions with HCPs/HCOs (see Transfers of Value). The Disclosure Code was required to be transposed into the national codes of all 33 EFPIA member associations by 1 January 2014. The full text of the Disclosure Code and other information about transparency reporting can be found here. |
| EFPIA Report                      | The local report of ToVs to Reportable Recipients as required by the EFPIA Disclosure Code. |
| Enterprise Resource Planning (ERP) | The system that enables Gilead to generate and manage purchase orders, invoices and other key business documents. |
| Gilead                            | Gilead Sciences Inc. and its Affiliates. |
### Gilead Affiliate

Any [Gilead](https://www.gilead.com) group company in any country, including those outside the EFPIA remit.

### Grant

Funding given to independent organisations, such as [HCOs](https://www.efpia.org), for particular projects.

### Healthcare Organisation (HCO)

The definition given in the [EFPIA Disclosure Code](https://www.efpia.org) is:

“Any legal person:

(i) that is a healthcare, medical or scientific association or organisation (irrespective of the legal or organisational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society (except for patient organisations within the scope of the EFPIA PO Code) whose business address, place of incorporation or primary place of operation is in Europe; or

(ii) through which one or more HCPs provide services.”

### Healthcare Professional (HCP)

The definition given in the [EFPIA Disclosure Code](https://www.efpia.org) is:

“Any natural person that is a member of the medical, dental, pharmacy or nursing professions or any other person who, in the course of his or her professional activities, may prescribe, purchase, supply, recommend or administer a medicinal product and whose primary practice, principal professional address or place of incorporation is in Europe. For the avoidance of doubt, the definition of HCP includes:

(i) any official or employee of a government agency or other organisation (whether in the public or private sector) that may prescribe, purchase, supply or administer medicinal products; and

(ii) any employee of a Member Company whose primary occupation is that of a practising HCP,

but excludes:

(x) all other employees of a Member Company; and

(y) a wholesaler or distributor of medicinal products.”

### Indirect Spend

Indirect spend means all [Transfers of Value](https://www.efpia.org) to a [Reportable Recipient](https://www.efpia.org) which are made by a [Third Party Vendor](https://www.efpia.org) on Gilead’s behalf.

### Investigator Sponsored Research

Research may be undertaken by individual [HCPs](https://www.efpia.org) and/or [HCOs](https://www.efpia.org) where they would like to investigate a particular aspect of a Gilead medicine. Gilead may choose to support this research by paying a Grant to the relevant [HCO](https://www.efpia.org).

### Patient Organisation

Patient organisations are not-for-profit organisations (including the umbrella organisations to which they belong), mainly composed of patients and/or caregivers, that represent and/or support the needs of patients and/or caregivers.

### Reportable Recipient

Means any [HCPs/HCOs](https://www.efpia.org) in relation to whom Gilead is required to disclose the [Transfers of Value](https://www.efpia.org) that it makes.

### Reportable Spend

All [Transfers of Value](https://www.efpia.org) made by any Gilead Affiliate, or by any third party on behalf of any Gilead Affiliate, to any [Reportable Recipient](https://www.efpia.org).

### Reporting Engine

The database and reporting system that holds ToV data and enables Gilead to produce the [EFPIA Reports](https://www.efpia.org) in the appropriate format and language for each EFPIA reporting country.

### Reporting Engine Provider

The software company that owns the [Reporting Engine](https://www.efpia.org) and maintains it for Gilead.

### Sponsorship

[Individual Sponsorship](https://www.efpia.org) – financial support for Reportable Recipients to attend educational events including travel, accommodation and/or registration fees.

[Event Sponsorship](https://www.efpia.org) – financial support for Third Party educational events.

### Third Party Vendors

Any agency (e.g. medical education agency, events agency, Contract Research Organisation)
which makes payments to Reportable Recipients on Gilead’s behalf.

<table>
<thead>
<tr>
<th>Transfer of Value (ToV)</th>
<th>A Transfer of Value means a direct or indirect benefit (whether money or money’s worth) given to a Reportable Recipient by Gilead.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>The ABPI Disclosure Code defines such transfers as follows:</td>
</tr>
<tr>
<td></td>
<td>“a direct or indirect transfer of value, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines. An indirect transfer of value is one made on behalf of a company for the benefit of a recipient, or through an intermediate and where the company knows or can identify the recipient that will benefit from the transfer of value.”</td>
</tr>
</tbody>
</table>